BAYRY - Bayer Aktiengesellschaft

Other OTC - Other OTC Delayed Price. Currency in USD
15.72
+0.09 (+0.55%)
As of 10:52AM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close15.63
Open15.69
Bid0.00 x 0
Ask0.00 x 0
Day's Range15.63 - 15.74
52 Week Range15.45 - 32.80
Volume118,485
Avg. Volume1,120,261
Market Cap59.289B
Beta (3Y Monthly)0.88
PE Ratio (TTM)8.52
EPS (TTM)1.84
Earnings DateN/A
Forward Dividend & Yield0.79 (4.70%)
Ex-Dividend Date2019-04-29
1y Target Est21.50
Trade prices are not sourced from all markets
  • Bayer hit by record $2 billion Roundup verdict
    Yahoo Finance Video7 days ago

    Bayer hit by record $2 billion Roundup verdict

    Yahoo Finance's Adam Shapiro, Julie Hyman and Rick Newman discuss.

  • Bayer to appeal $2 billion verdict in Roundup cancer lawsuit
    CBS News Videos7 days ago

    Bayer to appeal $2 billion verdict in Roundup cancer lawsuit

    Bayer, the company behind the maker of Roundup weed killer, plans to appeal a $2 billion verdict against it. On Monday a jury in California found the herbicide was linked to an elderly couple’s cancer. The judgement is the third since August against Monsanto’s parent company, Bayer. Anna Werner reports.

  • Bayer hires law firm to probe Monsanto data collection
    Reuters3 hours ago

    Bayer hires law firm to probe Monsanto data collection

    Bayer on Tuesday hired law firm Sidley Austin to investigate a Europe-wide data collection scheme run by its Monsanto unit, which targeted journalists, politicians and other stakeholders to influence the debate on pesticides. Bayer last week admitted that Monsanto, which it acquired for $63 billion last year, had gathered non-public information as part of the campaign, which French media said sought to influence the public debate on pesticides and genetically modified products. Bayer faces potentially heavy litigation costs from U.S. class-action lawsuits in which plaintiffs claim that its Roundup weedkiller, which contains glyphosate, causes cancer.

  • Top Deutsche Bank Investors Focusing Discontent on Chairman
    Bloomberg6 hours ago

    Top Deutsche Bank Investors Focusing Discontent on Chairman

    (Bloomberg) -- Some top Deutsche Bank AG investors are growing increasingly dissatisfied with supervisory board Chairman Paul Achleitner.

  • Compugen Ltd. (CGEN) Q1 2019 Earnings Call Transcript
    Motley Fool19 hours ago

    Compugen Ltd. (CGEN) Q1 2019 Earnings Call Transcript

    CGEN earnings call for the period ending March 31, 2019.

  • Bloomberg4 days ago

    A Dispatch From the Trade-War Front

    As expected, China retaliated against the U.S.’s increased tariffs by vowing this week to raise levies on $60 billion of goods, while also exploring other measures. Take these last two with a grain of salt, as it’s unclear how China would execute this kind of drastic action without painful consequences for itself. It’s unlikely China never buys a Boeing plane again, but the two fatal crashes of its 737 Max and the subsequent grounding of the jet make Boeing an easier target.

  • Pharma Stock Roundup: FDA Okays Line Extensions of LLY, PFE, ABBV Cancer Drugs
    Zacks4 days ago

    Pharma Stock Roundup: FDA Okays Line Extensions of LLY, PFE, ABBV Cancer Drugs

    FDA grants approval for line extensions of Lilly (LLY), Pfizer (PFE) and Roche (RHHBY)/AbbVie's (ABBV) cancer drugs

  • Reuters5 days ago

    Bayer bets on 'silver bullet' defense in Roundup litigation; experts see hurdles

    Bayer AG plans to argue that a $2 billion jury award and thousands of U.S. lawsuits claiming its glyphosate-based weed killer Roundup causes cancer should be tossed because a U.S. regulatory agency said the herbicide is not a public health risk. Some legal experts believe Bayer will have a tough time convincing appellate courts to throw out verdicts and lawsuits on those grounds. Bayer has a better shot if a business-friendly U.S. Supreme Court takes up the case, experts said.

  • Reuters5 days ago

    Bayer bets on 'silver bullet' defence in Roundup litigation; experts see hurdles

    Bayer AG plans to argue that a $2 billion jury award and thousands of U.S. lawsuits claiming its glyphosate-based weed killer Roundup causes cancer should be tossed because a U.S. regulatory agency said the herbicide is not a public health risk. Some legal experts believe Bayer will have a tough time convincing appellate courts to throw out verdicts and lawsuits on those grounds. Bayer has a better shot if a business-friendly U.S. Supreme Court takes up the case, experts said.

  • Reuters5 days ago

    Bayer confident of appeals of glyphosate weed killer court defeats - executive

    Bayer AG is confident its appeals of recent court rulings that its glyphosate weed killer Roundup caused cancer will be successful, a senior executive said on Thursday, amid a steep selloff of the company's shares this week. Liam Condon, president of Bayer's crop science division, said the appeals of jury rulings against the chemical will be heard by judges, a factor he sees as favourable to Bayer's chances. A California jury on Monday awarded more than $2 billion to a couple who claimed Bayer’s glyphosate-based Roundup weed killer caused their cancer, in the largest U.S. jury verdict to date against the company in litigation over the chemical.

  • Bayer confident of appeals of glyphosate weed killer court defeats: executive
    Reuters5 days ago

    Bayer confident of appeals of glyphosate weed killer court defeats: executive

    Bayer AG is confident its appeals of recent court rulings that its glyphosate weed killer Roundup caused cancer will be successful, a senior executive said on Thursday, amid a steep selloff of the company's shares this week. Liam Condon, president of Bayer's crop science division, said the appeals of jury rulings against the chemical will be heard by judges, a factor he sees as favorable to Bayer's chances. A California jury on Monday awarded more than $2 billion to a couple who claimed Bayer’s glyphosate-based Roundup weed killer caused their cancer, in the largest U.S. jury verdict to date against the company in litigation over the chemical.

  • Financial Times5 days ago

    Bayer’s woes point to a wider truth about Germany

    A clutch of journalists gathered in a swanky Berlin restaurant to hear all about the marvels and benefits of genetically modified foods — and to sample some of what sceptics dubbed “Franken foods”. The gathering, in the late 1990s, was all part of a charm offensive laid on by some German chemicals companies. Among those at the forefront of this endeavour was Monsanto of the US.

  • CNBC6 days ago

    The biggest breakthrough in agriculture to help feed the planet may come from outer space

    A four-year-old start-up called Indigo Ag is the No. 1 company on the 2019 CNBC Disruptor 50 list. Indigo Ag is out to feed the world and help farmers make a good living without harming the planet. Using satellite imaging and geospatial intelligence, it has created a living map of the world's food supply.

  • Barrons.com6 days ago

    Podcast: Bayer to Pay $2 Billion in Latest Roundup Case

    STOCKSTOWATCHTODAY BLOG Three numbers to start your day: Bayer is to Pay $2 Billion to a California Couple —A state jury in California decided Monday evening. It’s been almost one year since the German pharmaceutical company bought the U.

  • Why National Beverage, Tencent Music, and Bayer Slumped Today
    Motley Fool7 days ago

    Why National Beverage, Tencent Music, and Bayer Slumped Today

    See why these three stocks missed out on the broader market's rise on Tuesday.

  • Reuters7 days ago

    Corrected: More Roundup trials, appeals in store for Bayer after $2 billion verdict

    Bayer shares continued to fall on Tuesday after a California jury on Monday awarded more than $2 billion in damages to a couple who alleged that the company's glyphosate-based weed killer Roundup caused their cancers. The third successive loss by Bayer in U.S. courts and highest award to date by a jury after finding glyphosate to be carcinogenic highlights the legal risks and mounting cost to the company of the burgeoning litigation it faces over its widely-used herbicide. Bayer, which acquired Roundup maker Monsanto for $63 billion last year, denies the allegations, saying decades of studies and regulatory approvals have shown glyphosate and Roundup to be safe for human use.

  • Reuters7 days ago

    Factbox: More Roundup trials, appeals in store for Bayer after $2 billion verdict

    The third successive loss by Bayer in U.S. courts and highest award to date by a jury after finding glyphosate to be carcinogenic highlights the legal risks and mounting cost to the company of the burgeoning litigation it faces over its widely-used herbicide. Bayer, which acquired Roundup maker Monsanto for $63 billion last year, denies the allegations, saying decades of studies and regulatory approvals have shown glyphosate and Roundup to be safe for human use. Adverse jury verdicts have wiped more than 40% from Bayer's market value since August.

  • Bayer nears seven-year low after $2 billion award in Roundup trial
    Reuters7 days ago

    Bayer nears seven-year low after $2 billion award in Roundup trial

    Bayer shares fell by as much as 5 percent on Tuesday after a California couple were awarded more than $2 billion in the largest U.S. jury penalty over allegations its Roundup weed killer causes cancer. The stock closed at its lowest level in almost seven years, even though the punitive damages award is likely to be reduced due to U.S. Supreme Court rulings that limit the ratio of punitive to compensatory damages to 9:1. The jury set the total punitive damages at $2 billion and added $55 million in compensatory pay, concluding that Roundup - based on herbicide glyphosate - had been defectively designed, and that the company failed to warn of the herbicide's alleged cancer risk.

  • Barrons.com7 days ago

    Bayer Stock Is Falling on a $2 Billion Award in Roundup Cancer Lawsuit

    A state jury in California awarded nearly $2.1 billion on Monday evening to a California couple who had sued Monsanto over non-Hodgkin lymphoma diagnoses they blamed on the firm’s Roundup weed killer.

  • Ralph Lauren posts beat, changes at Tencent Music, more headaches for Boeing
    Yahoo Finance7 days ago

    Ralph Lauren posts beat, changes at Tencent Music, more headaches for Boeing

    Ralph Lauren, Tencent Music, Boeing, John Deere and Bayer are the companies to watch.

  • Lilly's Cyramza Gets FDA Nod for Second-Line Liver Cancer
    Zacks7 days ago

    Lilly's Cyramza Gets FDA Nod for Second-Line Liver Cancer

    Lilly's (LLY) Cyramza gets FDA approval to treat AFP-high hepatocellular carcinoma (HCC), a common form of liver cancer. FDA removes boxed warning from label.

  • Investors need to prepare for an extended period of economic warfare, says Deutsche
    MarketWatch7 days ago

    Investors need to prepare for an extended period of economic warfare, says Deutsche

    Our call of the day, from the chief investment office at DWS Investment Management (a unit of Deutsche Bank), warns the current trade dustup could be building into “something worse.”

  • Bloomberg7 days ago

    When Science Is No Match for a California Lawyer

    Bayer stresses there is no read-across from this particular case to others. Punitive damages in the first adverse trial verdict were cut from $250 million to $39 million. Bayer says Roundup is safe when used as directed, citing a recent study by the U.S. Environmental Protection Agency and 40 years of prior scientific data.

  • TheStreet.com7 days ago

    Bayer Shares Slump After $2 Billion Verdict in Latest Roundup Weed Killer Trial

    shares slumped to a near seven-year low Tuesday after a jury in California awarded more than $2 billion to a pair of plaintiffs who said the chemicals group's Roundup weed killer caused them to contract cancer. Alva and Alberta Pilliod were awarded $2 billion in punitive damages and $55 million in compensatory relief from the jury in Alameda County Superior Court in Oakland, California, the the third such ruling against the group linked to the weedkiller taken on from its $63 billion takeover of Monsanto. In the ruling, which Bayer described as "disappointing", the jury found that Roundup was defectively designed and that the company failed to warn users of its potential dangers.